Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint
By Stephen NakrosisShares of Contineum Therapeutics were trading lower after-hours Monday, following news a Phase 2 trial of an treatment for depression failed to meet its primary efficacy endpoint.Contineum said JNJ-5120/PIPE-307 is being developed by Johnson & Johnson under a global license and d…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.